Rosiglitazone Enhances the Apoptotic Effect of 5-fluorouracil in Colorectal Cancer Cells with High-glucose-induced Glutathione

Overview

Journal Sci Prog

Publisher Sage Publications

Specialty Science

Date 2019 Dec 5

PMID 31795844

Citations 4

Authors

Meng-Fei Lau

Kek-Heng Chua

Vikineswary Sabaratnam

Umah Rani Kuppusamy

Affiliations

Soon will be listed here.

Abstract

Colorectal cancer is one of the most prevalent noncommunicable diseases worldwide. 5-Fluorouracil is the mainstay of chemotherapy for colorectal cancer. Previously, we have demonstrated that high glucose diminishes the cytotoxicity of 5-fluorouracil by promoting cell cycle progression. The synergistic impact of rosiglitazone on 5-fluorouracil-induced apoptosis was further investigated in this study. Besides control cell lines (CCD-18Co), two human colonic carcinoma cell lines (HCT 116 and HT 29) were exposed to different treatments containing 5-fluorouracil, rosiglitazone or 5-fluorouracil/rosiglitazone combination under normal glucose (5.5 mM) and high-glucose (25 mM) conditions. The cellular oxidative stress level was evaluated with biomarkers of nitric oxide, advanced oxidation protein products, and reduced glutathione. The cell apoptosis was assessed using flow cytometry technique. High glucose caused the production of reduced glutathione in HCT 116 and HT 29 cells. Correspondingly, high glucose suppressed the apoptotic effect of 5-fluorouracil and rosiglitazone. As compared to 5-fluorouracil alone (2 µg/mL), addition of rosiglitazone significantly enhanced the apoptosis (increment rate of 5-20%) in a dose-dependent manner at normal glucose and high glucose levels. This study indicates that high-glucose-induced reduced glutathione confers resistance to apoptosis, but it can be overcome upon treatment of 5-fluorouracil and 5-fluorouracil/rosiglitazone combination. Rosiglitazone may be a promising antidiabetic drug to reduce the chemotherapeutic dose of 5-fluorouracil for colorectal cancer complicated with hyperglycemia.

Citing Articles

PPARG activation promotes the proliferation of colorectal cancer cell lines and enhances the antiproliferative effect of 5-fluorouracil.

Schockel L, Woischke C, Surendran S, Michl M, Schiergens T, Holscher A BMC Cancer. 2024; 24(1):234.

PMID: 38378472 PMC: 10877928. DOI: 10.1186/s12885-024-11985-5.

UCP2 as a Cancer Target through Energy Metabolism and Oxidative Stress Control.

Luby A, Alves-Guerra M Int J Mol Sci. 2022; 23(23).

PMID: 36499405 PMC: 9735768. DOI: 10.3390/ijms232315077.

Important players in carcinogenesis as potential targets in cancer therapy: an update.

Hermanowicz J, Kwiatkowska I, Pawlak D Oncotarget. 2020; 11(32):3078-3101.

PMID: 32850012 PMC: 7429179. DOI: 10.18632/oncotarget.27689.

Classifying the Linkage between Adipose Tissue Inflammation and Tumor Growth through Cancer-Associated Adipocytes.

Song Y, Lee S, Jin Y, Park H, Chun K, Lee H Mol Cells. 2020; 43(9):763-773.

PMID: 32759466 PMC: 7528682. DOI: 10.14348/molcells.2020.0118.

References

Patra K, Hay N . The pentose phosphate pathway and cancer. Trends Biochem Sci. 2014; 39(8):347-54. PMC: 4329227. DOI: 10.1016/j.tibs.2014.06.005. View

Vannini F, Kashfi K, Nath N . The dual role of iNOS in cancer. Redox Biol. 2015; 6:334-343. PMC: 4565017. DOI: 10.1016/j.redox.2015.08.009. View

Elmore S . Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007; 35(4):495-516. PMC: 2117903. DOI: 10.1080/01926230701320337. View

Huber S, Valente S, Chaimbault P, Schohn H . Evaluation of ∆2-pioglitazone, an analogue of pioglitazone, on colon cancer cell survival: Evidence of drug treatment association with autophagy and activation of the Nrf2/Keap1 pathway. Int J Oncol. 2014; 45(1):426-38. DOI: 10.3892/ijo.2014.2408. View

Fernald K, Kurokawa M . Evading apoptosis in cancer. Trends Cell Biol. 2013; 23(12):620-33. PMC: 4091735. DOI: 10.1016/j.tcb.2013.07.006. View

Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T . Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012; 9(7):676-82. PMC: 3855844. DOI: 10.1038/nmeth.2019. View

Al-Keilani M, Alsmadi D, Darweesh R, Alzoubi K . Pramlintide, an antidiabetic, is antineoplastic in colorectal cancer and synergizes with conventional chemotherapy. Clin Pharmacol. 2018; 10:23-29. PMC: 5842772. DOI: 10.2147/CPAA.S153780. View

Mates J, Segura J, Alonso F, Marquez J . Oxidative stress in apoptosis and cancer: an update. Arch Toxicol. 2012; 86(11):1649-65. DOI: 10.1007/s00204-012-0906-3. View

Chung F, Huang M, Yeh C, Chang H, Cheng T, Yen L . GLUT1 gene is a potential hypoxic marker in colorectal cancer patients. BMC Cancer. 2009; 9:241. PMC: 3087329. DOI: 10.1186/1471-2407-9-241. View

10.

Yan L . Pathogenesis of chronic hyperglycemia: from reductive stress to oxidative stress. J Diabetes Res. 2014; 2014:137919. PMC: 4082845. DOI: 10.1155/2014/137919. View

11.

Gamcsik M, Kasibhatla M, Teeter S, Colvin O . Glutathione levels in human tumors. Biomarkers. 2012; 17(8):671-91. PMC: 3608468. DOI: 10.3109/1354750X.2012.715672. View

12.

Nita M, Nagawa H, Tominaga O, Tsuno N, Fujii S, Sasaki S . 5-Fluorouracil induces apoptosis in human colon cancer cell lines with modulation of Bcl-2 family proteins. Br J Cancer. 1998; 78(8):986-92. PMC: 2063141. DOI: 10.1038/bjc.1998.617. View

13.

Zhang W, Xu Y, Xu Q, Shi H, Shi J, Hou Y . PPARδ promotes tumor progression via activation of Glut1 and SLC1-A5 transcription. Carcinogenesis. 2017; 38(7):748-755. DOI: 10.1093/carcin/bgx035. View

14.

Gerards M, van der Velden D, Baars J, Brandjes D, Hoekstra J, Vriesendorp T . Impact of hyperglycemia on the efficacy of chemotherapy-A systematic review of preclinical studies. Crit Rev Oncol Hematol. 2017; 113:235-241. DOI: 10.1016/j.critrevonc.2017.03.007. View

15.

Sheng H, Shao J, Morrow J, Beauchamp R, DuBois R . Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res. 1998; 58(2):362-6. View

16.

Miao R, Xu T, Liu L, Wang M, Jiang Y, Li J . Rosiglitazone and retinoic acid inhibit proliferation and induce apoptosis in the HCT-15 human colorectal cancer cell line. Exp Ther Med. 2012; 2(3):413-417. PMC: 3440746. DOI: 10.3892/etm.2011.227. View

17.

Eberhart C, Coffey R, Radhika A, Giardiello F, Ferrenbach S, DuBois R . Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 1994; 107(4):1183-8. DOI: 10.1016/0016-5085(94)90246-1. View

18.

Johnson S, Gulhati P, Rampy B, Han Y, Rychahou P, Doan H . Novel expression patterns of PI3K/Akt/mTOR signaling pathway components in colorectal cancer. J Am Coll Surg. 2010; 210(5):767-76, 776-8. PMC: 2895913. DOI: 10.1016/j.jamcollsurg.2009.12.008. View

19.

Yang W, FRUCHT H . Activation of the PPAR pathway induces apoptosis and COX-2 inhibition in HT-29 human colon cancer cells. Carcinogenesis. 2001; 22(9):1379-83. DOI: 10.1093/carcin/22.9.1379. View

20.

Granchi C, Fortunato S, Minutolo F . Anticancer agents interacting with membrane glucose transporters. Medchemcomm. 2017; 7(9):1716-1729. PMC: 5198910. DOI: 10.1039/C6MD00287K. View